4.6 Article

Diabetic ketoacidosis

Journal

NATURE REVIEWS DISEASE PRIMERS
Volume 6, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41572-020-0165-1

Keywords

-

Funding

  1. American Diabetes Association (ADA) [1-17-IBS-186]
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U34DK123894]
  3. Fondo Nacional de Ciencia y Tecnologia (FONDECYT) from the Government of Chile [1170895]
  4. National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) from the Clinical and Translational Science Award program [UL1TR002378]
  5. NIH [U30, P30DK11102]
  6. Dexcom
  7. Novo Nordisk
  8. Sanofi

Ask authors/readers for more resources

Diabetic ketoacidosis (DKA) is the most common acute hyperglycaemic emergency in people with diabetes mellitus. A diagnosis of DKA is confirmed when all of the three criteria are present - 'D', either elevated blood glucose levels or a family history of diabetes mellitus; 'K', the presence of high urinary or blood ketoacids; and 'A', a high anion gap metabolic acidosis. Early diagnosis and management are paramount to improve patient outcomes. The mainstays of treatment include restoration of circulating volume, insulin therapy, electrolyte replacement and treatment of any underlying precipitating event. Without optimal treatment, DKA remains a condition with appreciable, although largely preventable, morbidity and mortality. In this Primer, we discuss the epidemiology, pathogenesis, risk factors and diagnosis of DKA and provide practical recommendations for the management of DKA in adults and children.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available